BioAge Labs (BIOA) Current Deferred Revenue (2023 - 2026)

BioAge Labs has disclosed Current Deferred Revenue across 4 years of filings, most recently posting $4.4 million for Q2 2026.

• In Q2 2026, Current Deferred Revenue fell 43.32% year-over-year to $4.4 million; the TTM figure through Jun 2026 stood at $4.4 million (down 43.32% YoY), while the FY2025 annual figure was $5.8 million, down 26.48% from the prior year.
• Current Deferred Revenue came in at $4.4 million for Q2 2026 at BioAge Labs, down from $6.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $8.2 million in Q1 2025 to a low of $3.3 million in Q4 2023.
• Average Current Deferred Revenue over 4 years is $6.4 million, with a median of $6.8 million recorded in 2025.
• Year-over-year, Current Deferred Revenue soared 136.22% in 2024 and plunged 43.32% in 2026.
• Over 4 years, Current Deferred Revenue stood at $3.3 million in 2023, then jumped by 136.22% to $7.8 million in 2024, then fell by 26.48% to $5.8 million in 2025, then fell by 24.17% to $4.4 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $4.4 million in Q2 2026, $6.2 million in Q1 2026, and $5.8 million in Q4 2025.